Physician profile
Michael E Markowski
NPI 1295774057
$3,064.80
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $144 · 2021: $711 · 2022: $1,173 · 2023: $343 · 2024: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $608.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $755.59 | 2021-2024 | |
| Lilly USA, LLC | $427.88 | 2019-2024 | Kisunla, Emgality, Reyvow |
| Genzyme Corporation | $277.36 | 2019-2023 | |
| Amneal Pharmaceuticals LLC | $165.69 | 2019-2022 | |
| Lundbeck LLC | $149.34 | 2022-2023 | Vyepti |
| Allergan, INC. | $133.46 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $131.87 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $121.46 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $114.67 | 2019-2022 | |
| Biogen, INC. | $79.34 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $71.60 | 2022 | |
| Mdd US Operations, LLC | $69.22 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $67.04 | 2019-2022 | |
| Eisai INC. | $49.63 | 2022 | |
| Avion Pharmaceuticals | $41.50 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $37.28 | 2021 | |
| Kyowa Kirin, INC. | $35.23 | 2021-2022 | |
| Acorda Therapeutics, INC | $34.89 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $34.42 | 2019 | |
| Medtronic, INC. | $32.12 | 2022 | |
| Sk Life Science, INC. | $29.55 | 2022 | |
| Celgene Corporation | $28.39 | 2022 | |
| Genentech USA, INC. | $24.68 | 2019 | |
| Boston Scientific Corporation | $23.75 | 2020 | |
| Adamas Pharmaceuticals, INC. | $20.81 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $20.01 | 2022 | |
| Csl Behring | $20.00 | 2019 | |
| Amgen INC. | $18.55 | 2021 | |
| Avanir Pharmaceuticals, INC. | $18.10 | 2022 | |
| Medtronic Vascular, INC. | $17.73 | 2019 | |
| Grifols USA, LLC | $13.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Markowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.